research Efficacy of Compound GV-350 with Tricofer Iron, Cystine, and Biotin in the Management of Telogen Effluvium in Women with Iron Deficiency
GV-350 improves hair growth and quality of life in iron-deficient women without side effects.
Search
forLearn
0 / 0 results — no results
Research
5 / 916 results research MCMV Infection Lowers the Threshold for the Development of Clinical GvHD After Allogeneic Bone Marrow Transplantation
CMV infection increases the risk of GvHD after bone marrow transplants.
research Ruxolitinib Protects Skin Stem Cells And Maintains Skin Homeostasis In Murine Graft-Versus-Host Disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-Versus-Host Disease
Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.
research Graft-Versus-Host Reaction: Cutaneous Manifestations Following Bone Marrow Transplantation
Skin changes help detect graft-versus-host reaction early after bone marrow transplants.
Community Join
5 / 21 resultscommunity Trump halted all federal funding for medical research in the US. Will this affect any current treatments in the pipeline?
Federal funding for medical research in the U.S. has been halted, potentially delaying new treatments. Hair loss treatments like finasteride and minoxidil are unlikely to be impacted as they are typically funded by private companies.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community Guys… Pelage might just be the one. They might actually find the cure. I work in tech - let me explain.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
community New Study: PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and stimulate natural hair growth by 20%
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
community PP405 is nothing but a scam and Pelage know it.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.